Panellists in this video:
+ Ms Viveka Roychowdhury, Editor, Express Pharma (MODERATOR)
+ Mr Ankur Shah, Founder & Chairman, Invengene
+ Mr Atul Shastri, President – Global Operations, Eugia Pharma Specialities
+ Mr Raja Bhanu, DG, Pharmexcil
Key Highlights:
[1] Early collaboration and globally scalable product design are becoming critical to de-risk investments and secure long-term partnerships.
[2] Success in injectables will depend on the ability to take products from the bench to the floor. We need to integrate manufacturing complexity and supply chain considerations from the very start.
[3] India builds world-class plants but not equivalent R&D ecosystems. The gap between lab and large-scale production is where compliance and sterility challenges emerge.
[4] AI, ML, and IoT can reduce human error, ensure sterility (a binary outcome), and significantly compress timelines — positioning India to lead in next-gen injectable innovation.
[5] While India advances in affordability, scale, and AI-driven innovation, human expertise remains central, and self-reliance must be built to withstand geopolitical risks.
[6] Amid rising geopolitical tensions, building self-reliance through strong domestic networks is critical to prevent supply disruptions, and while this transition will take time, the groundwork must begin immediately.